P2-847 Late presenting girls with Turner Syndrome can achieve a normal final height.

Sophia Sakka, Prof. Nick Shaw, Prof. Jeremy Kirk
Department of Endocrinology and Diabetes, Birmingham Children's Hospital, Birmingham, UK

Background:

• The diagnosis of Turner Syndrome (TS) must be included in the differential diagnosis of all girls with short stature.

• Despite overall earlier diagnosis and treatment there still remain patients with TS who present late with delayed puberty.

• Although growth hormone (GH) is known to increase final height (FH) in girls with TS, little evidence exists on treatment in late-presenting girls.

Objective

• To assess the effect of late GH treatment along with delayed pubertal induction on FH of girls with TS.

Study Population and Methods

• 13 girls with TS presenting after 12 years of age due to delayed puberty were studied.

• Standard GH treatment was initiated immediately after diagnosis (starting dose 40mcg/kg/d).

• 8/13 were also started on the anabolic steroid oxandrolone at the same time.

• FH was calculated when the height velocity was ≦ 2cm/year.

Results

	Minimum	Maximum	Mean	Std. Deviation
age at initiation of GH (years)	11.92	16.92	14.37	1.72
age at initiation of oestrogen (years)	13.08	17.50	15.21	1.31
Δ age GH to oestrogen initiation (years)	-0.50	1.75	0.70	0.62
Final height (cm)	151.2	165	156.9	4.2



• The FH range was 151.2-165 cm ie. within the normal range for girls without TS.

•There was no statistically significant difference in FH-SDS between those patients who received oxandrolone and those who did not.

Conclusion

We have shown that despite late GH treatment in girls with TS presenting with delayed puberty, a normal FH can be achieved. Previous studies have shown that late pubertal induction, as well as oxandrolone treatment, improve FH (1,2), factors that seem to have had a positive effect in our patients.

Literature

1. Effect of oxandrolone and timing of pubertal induction on final height in Turner's syndrome: randomised, double blind, placebo controlled trial EJ Gault, R Perry,T Cole, S Casey, W Paterson, P Hindmarsh, P Betts, D Dunger, M Donaldson. BMJ 2011;342:d1980

2. **Major Determinants of Height Development in Turner Syndrome (TS) Patients Treated With GH: Analysis of 987 Patients From KIGS M Ranke, A Lindberg, AK Albertsson-Wikland, D Dunger, WS Cutfield, M Tauber, P Wilton, H Wollmann, E Reiter** on behalf of the KIGS International Board Ped Res 2007:61(1);105-110

All authors have nothing to declare

DOI: 10.3252/pso.eu.55ESPE.2016
Poster presented at: ESPE 2016 PARIS